Sogroya FDA Approval History
Last updated by Judith Stewart, BPharm on Sep 3, 2020.
Sogroya (somapacitan-beco) is a human growth hormone analog indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.
- Sogroya is administered by subcutaneous injection into the abdomen or thigh one time each week.
- Common side effects (≥2%) include back pain, arthralgia, dyspepsia, sleep disorder, dizziness, tonsillitis, peripheral edema, vomiting, adrenal insufficiency, hypertension, blood creatine phosphokinase increase, weight increase, anemia.
Development timeline for Sogroya
|Aug 28, 2020||Approval FDA Approves Sogroya (somapacitan-beco) a Once-Weekly Treatment for Adult Growth Hormone Deficiency|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.